» Articles » PMID: 35846308

The Essential Role of Body Weight in Adjusting Gn Dosage to Prevent High Ovarian Response for Women With PCOS During IVF: A Retrospective Study

Overview
Specialty Endocrinology
Date 2022 Jul 18
PMID 35846308
Authors
Affiliations
Soon will be listed here.
Abstract

Polycystic ovarian syndrome (PCOS) is the major cause of anovulatory infertility. Since women with PCOS are often accompanied by increased body weight and hyper response to controlled ovarian stimulation, individualized gonadotropin (Gn) dose is required to achieve a therapeutic effect while minimizing the risk of ovarian hyperstimulation simultaneously. We aimed to investigate the essential role of body weight in optimizing initial Gn dosage for PCOS patients during fertilization (IVF). We retrospectively included 409 infertile PCOS patients who used gonadotropin-releasing hormone (GnRH)-antagonist fixed protocol and underwent their first cycle of IVF in West China Second University Hospital from January 2019 to June 2021. Baseline characteristics controlled ovarian stimulation parameters, and reproductive outcomes were compared between patients with different body weights and different ovarian responses. Multivariable linear regression analyses were adopted to investigate the relationship between body weight and initial Gn dosage. Receiver operating characteristic (ROC) curves were drawn to find the optimal cut-off value of body weight in predicting the starting Gn dosage so as to prevent high ovarian response (HOR). We found that luteinizing hormone (LH) level and Anti-Mullerian hormone (AMH) level were lowest in the group with body weight over 70 kg and was highest in the group with body weight less than 50 kg. Increased body weight was significantly correlated to the rise of initial Gn dosage (Beta = 0.399, t = 8.921, p < 0.001). Normal ovarian response (NOR) patients had significantly less fresh cycle cancel rate and ovarian hyperstimulation syndrome (OHSS) rate which outweighed the fewer embryos compared with HOR patients. Using ROC curves, 53.25 kg (sensitivity, 84.2%; specificity, 53.8%) and 70.5 kg (sensitivity, 58.8%; specificity, 93.0%) were identified as the optimal cut-off values to predict the initial Gn dosage of no more than 150 IU and 225 IU, respectively. In conclusion, adjusting the initial Gn dosage based on body weight is crucial to preventing ovarian hyperstimulation while not influencing reproductive outcomes for PCOS patients during IVF.

Citing Articles

Relationship between CCL25/CCR9 Levels in Follicular Fluid and High Ovarian Response in Patients with Polycystic Ovary Syndrome.

Hao Y, Yin Q, Hu F, Liu X, Yang Y, Sun F Int J Endocrinol. 2024; 2024:2449037.

PMID: 39411316 PMC: 11479777. DOI: 10.1155/2024/2449037.


Free Androgen Index Might Not Be a Perfect Predictor of Infertility Outcomes in Patients with Polycystic Ovary Syndrome Undergoing Frozen Embryo Transfer:A Retrospective Cohort Study.

Wang S, Tan J, Wang C, Huang J, Zhou C Int J Womens Health. 2024; 16:1349-1359.

PMID: 39135910 PMC: 11318606. DOI: 10.2147/IJWH.S465541.


Clinical evidence of coenzyme Q10 pretreatment for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis.

Lin G, Li X, Yie S, Xu L Ann Med. 2024; 56(1):2389469.

PMID: 39129455 PMC: 11321116. DOI: 10.1080/07853890.2024.2389469.


Effect of GnRH agonist trigger with or without low-dose hCG on reproductive outcomes for PCOS women with freeze-all strategy: a propensity score matching study.

Wang Q, Wan Q, Li T, Wang X, Hu Y, Zhong Z Arch Gynecol Obstet. 2023; 309(2):679-688.

PMID: 38032411 DOI: 10.1007/s00404-023-07285-1.

References
1.
Ferraretti A, La Marca A, Fauser B, Tarlatzis B, Nargund G, Gianaroli L . ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011; 26(7):1616-24. DOI: 10.1093/humrep/der092. View

2.
Abbara A, Patel A, Hunjan T, Clarke S, Chia G, Eng P . FSH Requirements for Follicle Growth During Controlled Ovarian Stimulation. Front Endocrinol (Lausanne). 2019; 10:579. PMC: 6718557. DOI: 10.3389/fendo.2019.00579. View

3.
Rombauts L . Is there a recommended maximum starting dose of FSH in IVF?. J Assist Reprod Genet. 2007; 24(8):343-9. PMC: 3454944. DOI: 10.1007/s10815-007-9134-9. View

4.
Waki M, Kral J, Mazariegos M, Wang J, Pierson Jr R, Heymsfield S . Relative expansion of extracellular fluid in obese vs. nonobese women. Am J Physiol. 1991; 261(2 Pt 1):E199-203. DOI: 10.1152/ajpendo.1991.261.2.E199. View

5.
Guo Y, Jiang H, Hu S, Liu S, Li F, Jin L . Efficacy of three COS protocols and predictability of AMH and AFC in women with discordant ovarian reserve markers: a retrospective study on 19,239 patients. J Ovarian Res. 2021; 14(1):111. PMC: 8403432. DOI: 10.1186/s13048-021-00863-4. View